NeoTYPE Precision Profile for Solid Tumors
Commercial solid-tumor molecular profiling panel combining targeted NGS with IHC and reflex assays to support treatment selection.
- Developer
- NeoGenomics
- Intended use
- Other
- Cancer scope
- Solid tumors
- Specimen
- FFPE tumor tissue
- Molecular modality
- DNA mutation, Protein
- Current version
- NeoTYPE Precision Profile current 83-biomarker configuration (2026)
- Evidence context
- 0 structured studies · 0 indexed performance results · 2 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.